Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
38 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Valneva SE - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Valneva SE - Product Pipeline Review - 2014', provides an overview of the Valneva SE's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Valneva SE's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Valneva SE including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Valneva SE's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Valneva SE's pipeline products Reasons to buy - Evaluate Valneva SE's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Valneva SE in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Valneva SE's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Valneva SE and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Valneva SE - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Valneva SE and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Valneva SE Snapshot 5 Valneva SE Overview 5 Key Information 5 Key Facts 5 Valneva SE - Research and Development Overview 6 Key Therapeutic Areas 6 Valneva SE - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Partnered Products 10 Partnered Products/Combination Treatment Modalities 11 Pipeline Products - Out-Licensed Products 12 Out-Licensed Products/Combination Treatment Modalities 13 Valneva SE - Pipeline Products Glance 14 Valneva SE - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 Phase I Products/Combination Treatment Modalities 15 Valneva SE - Early Stage Pipeline Products 16 Preclinical Products/Combination Treatment Modalities 16 Discovery Products/Combination Treatment Modalities 17 Valneva SE - Drug Profiles 18 VLA-43 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Vaccine for Undisclosed Indication 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 VLA-84 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Monoclonal Antibodies for Cancer 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 VLA-15 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Antibodies for Pneumococcus Infections 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Monoclonal Antibodies for Infectious Disease 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Valneva SE - Pipeline Analysis 26 Valneva SE - Pipeline Products by Target 26 Valneva SE - Pipeline Products by Route of Administration 27 Valneva SE - Pipeline Products by Molecule Type 28 Valneva SE - Recent Pipeline Updates 29 Valneva SE - Dormant Projects 33 Valneva SE - Discontinued Pipeline Products 34 Discontinued Pipeline Product Profiles 34 IC-41 34 IC-47 34 Vaccine for Travelers Diarrhea 34 VLS-732 34 VLS-801 35 Valneva SE - Locations And Subsidiaries 36 Head Office 36 Other Locations & Subsidiaries 36 Appendix 37 Methodology 37 Coverage 37 Secondary Research 37 Primary Research 37 Expert Panel Validation 37 Contact Us 38 Disclaimer 38
List of Tables Valneva SE, Key Information 5 Valneva SE, Key Facts 5 Valneva SE - Pipeline by Indication, 2014 7 Valneva SE - Pipeline by Stage of Development, 2014 8 Valneva SE - Monotherapy Products in Pipeline, 2014 9 Valneva SE - Partnered Products in Pipeline, 2014 10 Valneva SE - Partnered Products/ Combination Treatment Modalities, 2014 11 Valneva SE - Out-Licensed Products in Pipeline, 2014 12 Valneva SE - Out-Licensed Products/ Combination Treatment Modalities, 2014 13 Valneva SE - Phase II, 2014 14 Valneva SE - Phase I, 2014 15 Valneva SE - Preclinical, 2014 16 Valneva SE - Discovery, 2014 17 Valneva SE - Pipeline by Target, 2014 26 Valneva SE - Pipeline by Route of Administration, 2014 27 Valneva SE - Pipeline by Molecule Type, 2014 28 Valneva SE - Recent Pipeline Updates, 2014 29 Valneva SE - Dormant Developmental Projects,2014 33 Valneva SE - Discontinued Pipeline Products, 2014 34 Valneva SE, Subsidiaries 36
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.